AVF Failure: How RP105 Deficiency Aggravates the Remodeling Process
"New research sheds light on the critical role of RP105 in arteriovenous fistula (AVF) maturation and failure, offering potential therapeutic targets for improving outcomes."
Arteriovenous fistulas (AVFs) are a lifeline for hemodialysis patients, but their high failure rate presents a significant clinical challenge. When an AVF fails to mature properly, it leads to increased morbidity and limits effective dialysis treatment. Understanding the complex mechanisms behind AVF maturation failure is crucial for developing better interventions.
Key factors in AVF success include outward remodeling (the widening of the vein), controlled inflammation, and the behavior of vascular smooth muscle cells (VSMCs). Researchers are actively investigating these areas to identify potential therapeutic targets that can improve AVF patency and reduce failure rates.
A recent study has focused on RP105, a protein that regulates TLR4 signaling, which plays a role in immune responses and inflammation. By examining how RP105 deficiency affects AVF maturation in a mouse model, the research team has uncovered new insights into the interplay between inflammation and VSMC function, potentially paving the way for novel therapeutic strategies.
Liposomal Prednisolone and Venous Remodeling
In a murine arteriovenous fistula model, mice treated with liposomal prednisolone (L-Pred) had a 27% larger external jugular vein circumference 14 days after surgery than mice treated with PBS (P = 0.004). The study reported no significant circumference difference for prednisolone-treated mice (P = 0.195) or liposomal PBS-treated mice (P = 0.396), compared with the PBS group.
From the Quinton-Scribner Shunt to the AVF
Reliable, repeatable vascular access for outpatient hemodialysis began in the 1960s with the Quinton-Scribner shunt. The autologous Brescia-Cimino radial-cephalic arteriovenous fistula followed and dominated hemodialysis vascular access for the next 20 years. A separate historical account identifies Dr. Kenneth Charles Appell as the person who first introduced the radiocephalic AVF, which enabled hemodialysis for people with chronic kidney disease; another describes its creation as a milestone in vascular surgery.
RP105's Role in AVF Maturation and Remodeling
The study revealed that mice lacking RP105 exhibited a 26% decrease in venous outward remodeling, a critical process for successful AVF maturation. Further investigation showed that RP105 influences the inflammatory response and VSMC function within the AVF.
- Reduced Venous Outward Remodeling: RP105 deficiency significantly impairs the widening of the vein, a crucial step for effective dialysis.
- Impaired Inflammatory Response: RP105 deficiency leads to an imbalance in immune cell populations, disrupting the natural healing process.
- Decreased VSMC Content: The amount of VSMCs, critical for vessel wall remodeling, is markedly reduced in RP105-deficient AVFs.
- Altered VSMC Function: RP105 deficiency impairs both the proliferation and migration capabilities of VSMCs, hindering proper vessel adaptation.
RP105 and Vascular Smooth Muscle Cell Remodeling
A 2025 review reports that in RP105-deficient (RP105−/−) mice with an AVF, vascular smooth muscle cells shift toward a regenerative phenotype and show reduced proliferation, alongside impaired venous outward remodeling. Another review notes that vascular smooth muscle cells share the immune-cell regulatory factor TLR4 and that removing RP105 affected both cell types in similar ways. In studies using a murine AVF model, 14 days after surgery is described as the gold-standard follow-up point for examining AVF maturation.
Functional Measurements Remain a Gap
The study of RP105 deficiency and AVF remodeling identifies a limitation for future research: studies should include blood-flow measurements. Its authors describe blood-flow rate as a critical functional parameter of an AVF. Thus, remodeling findings alone do not provide that flow measurement.
RP105 Deficiency and AVF Access Comparisons
In a murine AVF study, RP105−/− mice had a 26% smaller external jugular vein circumference than wild-type mice (P = 0.03). In clinical hemodialysis access, an AVF has been described as the gold standard for more than 50 years, with reported advantages over alternative access modalities including better long-term survival, fewer interventions to maintain patency, lower infection rates, and lower health-care expenditure. The supplied sources also describe endovascular AVF creation as a minimally invasive alternative to traditional surgical AVF creation, and report that a 2026 review compared AVFs and grafts in more than 260,000 hemodialysis patients.
Implications and Future Directions
This research provides valuable insights into the role of RP105 in AVF maturation failure. By demonstrating how RP105 deficiency affects inflammation, outward remodeling, and VSMC function, the study identifies potential targets for therapeutic intervention.
AVF Failure in Hemodialysis Care
A 2021 retrospective study describes the AVF as the preferred vascular access for hemodialysis and reports primary failure in 20–60% of cases. It examined clinical and vascular factors associated with failure among patients who underwent AVF creation from January 2017 to December of the same year. Another source states that National Kidney Foundation Kidney Disease Outcomes Quality Initiative criteria rank the AVF as the best-access method for hemodialysis, and that the Fistula First initiative recommends AVF formation for most patients. A 2025 study describes AVF failure as affecting dialysis quality and patient prognosis and set out to analyze associated factors and establish a nomogram prediction model.
The findings suggest that strategies aimed at modulating RP105 activity, or its downstream effects on immune cells and VSMCs, could improve AVF patency and reduce failure rates. Future research should focus on developing cell-specific targeting approaches to precisely manipulate RP105 signaling within the AVF.
Ultimately, a better understanding of the complex interplay between inflammation and VSMC function will lead to more effective strategies for preventing AVF failure and improving the lives of hemodialysis patients.